TR200102403T2 - Piridopiranoazepin türevleri, bunların hazırlanmaları ve terapötik uygulamaları. - Google Patents

Piridopiranoazepin türevleri, bunların hazırlanmaları ve terapötik uygulamaları.

Info

Publication number
TR200102403T2
TR200102403T2 TR2001/02403T TR200102403T TR200102403T2 TR 200102403 T2 TR200102403 T2 TR 200102403T2 TR 2001/02403 T TR2001/02403 T TR 2001/02403T TR 200102403 T TR200102403 T TR 200102403T TR 200102403 T2 TR200102403 T2 TR 200102403T2
Authority
TR
Turkey
Prior art keywords
alkyl
group
hydrogen
preparation
therapeutic applications
Prior art date
Application number
TR2001/02403T
Other languages
English (en)
Inventor
Galli Frederic
Jegham Samir
Lochead Alistair
Samson Axelle
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of TR200102403T2 publication Critical patent/TR200102403T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Genel formül (I)'deki bilesikler olup, söz konusu formül içerisindeki, R1, bir hidrojen atomu, bir alkil, fenialkil, fenilhidroksialkil, furanilalkil veya furanilhidroksialkil gurubudur, R2; bir hidrojen veya halojen atomu veya bir triflorometil, siyano hidroksil, nitro, asetil, alkil, alkoksi veya içerisinde, R4 ve R5'in, her birinin bir hidrojen atomu veya bir alkil grubu oldugu veya bunlari tasiyan nitrojen atomu ile birlikte, bir C4-C7 halkasini olusturdugu, NR4R5 genel formülüne sahip bir amino grubu veya bir halojen atomu veya bir triflorometil, triflorometoksi, siyano, hidroksil, nitro, asetil, alkil, alkoksi veya metilendioksi grubu ile istege bagli olarak substitüsyonlu bir fenil veya naftil grubudur ve R3; bir hidrojen veya halojen atomu veya bir alkil grubudur.
TR2001/02403T 1999-03-05 2000-03-01 Piridopiranoazepin türevleri, bunların hazırlanmaları ve terapötik uygulamaları. TR200102403T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902784A FR2790474B1 (fr) 1999-03-05 1999-03-05 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
TR200102403T2 true TR200102403T2 (tr) 2001-12-21

Family

ID=9542888

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02403T TR200102403T2 (tr) 1999-03-05 2000-03-01 Piridopiranoazepin türevleri, bunların hazırlanmaları ve terapötik uygulamaları.

Country Status (37)

Country Link
US (2) US6538003B1 (tr)
EP (1) EP1161434B1 (tr)
JP (1) JP4806123B2 (tr)
KR (2) KR20070086359A (tr)
CN (1) CN1137894C (tr)
AR (1) AR022820A1 (tr)
AT (1) ATE231869T1 (tr)
AU (1) AU764625B2 (tr)
BG (1) BG65211B1 (tr)
BR (1) BR0008763A (tr)
CA (1) CA2372063C (tr)
CO (1) CO5160250A1 (tr)
CZ (1) CZ302259B6 (tr)
DE (1) DE60001307T2 (tr)
DK (1) DK1161434T3 (tr)
EE (1) EE04497B1 (tr)
ES (1) ES2191611T3 (tr)
FR (1) FR2790474B1 (tr)
HK (1) HK1040398B (tr)
HR (1) HRP20010655B1 (tr)
HU (1) HU228671B1 (tr)
ID (1) ID30116A (tr)
IL (2) IL145150A0 (tr)
MX (1) MXPA01008972A (tr)
NO (1) NO327119B1 (tr)
NZ (1) NZ513561A (tr)
PE (1) PE20001543A1 (tr)
PL (1) PL201683B1 (tr)
RS (1) RS49997B (tr)
RU (1) RU2238273C2 (tr)
SK (1) SK284339B6 (tr)
TR (1) TR200102403T2 (tr)
TW (1) TWI222975B (tr)
UA (1) UA61164C2 (tr)
UY (1) UY26048A1 (tr)
WO (1) WO2000053608A1 (tr)
ZA (1) ZA200106811B (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0312297A (pt) 2002-07-18 2005-04-12 Cytos Biotechnology Ag Conjugados veìculos de hapteno e seu uso
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
DK1949901T3 (da) * 2002-12-06 2014-05-19 The Feinstein Inst Medical Res Fremgangsmåde til bestemmelse af en cholinerg agonist selektiv for en alfa-7-nikotinsk receptor
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
US20090076059A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dianicline
US8703774B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
EP2231643B1 (de) 2007-12-07 2012-10-31 Abbott GmbH & Co. KG Amidomethyl-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
RU2484090C2 (ru) * 2007-12-07 2013-06-10 Эбботт Гмбх Унд Ко.Кг 5-галогензамещенные производные оксиндола и их применение для лечения вазопрессинзависимых заболеваний
MX2010006204A (es) 2007-12-07 2011-03-16 Abbott Gmbh & Co Kg Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
WO2009146031A1 (en) 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
MY159826A (en) 2008-11-19 2017-02-15 Forum Pharmaceuticals Inc Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
EP2435080A2 (en) * 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
EP0853621A1 (en) * 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
FR2761072B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
JP2002500652A (ja) * 1997-05-30 2002-01-08 ニューロサーアチ・アクティーゼルスカブ スピロ−キヌクリジン誘導体、その製造方法及びその使用方法
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
CN1137894C (zh) 2004-02-11
UY26048A1 (es) 2000-09-29
CA2372063C (en) 2011-01-11
DK1161434T3 (da) 2003-05-26
DE60001307D1 (de) 2003-03-06
KR100768355B1 (ko) 2007-10-17
RS49997B (sr) 2008-09-29
FR2790474A1 (fr) 2000-09-08
HRP20010655A2 (en) 2002-08-31
JP2002539129A (ja) 2002-11-19
NZ513561A (en) 2003-06-30
HUP0201753A3 (en) 2004-12-28
CA2372063A1 (en) 2000-09-14
HK1040398B (zh) 2003-07-18
NO20014270L (no) 2001-11-05
IL145150A (en) 2007-06-03
AU764625B2 (en) 2003-08-28
RU2238273C2 (ru) 2004-10-20
HK1040398A1 (en) 2002-06-07
NO20014270D0 (no) 2001-09-03
YU59601A (sh) 2004-03-12
CO5160250A1 (es) 2002-05-30
SK284339B6 (sk) 2005-02-04
WO2000053608A1 (fr) 2000-09-14
IL145150A0 (en) 2002-06-30
US6538003B1 (en) 2003-03-25
SK12422001A3 (sk) 2002-04-04
ES2191611T3 (es) 2003-09-16
MXPA01008972A (es) 2002-03-27
KR20010102492A (ko) 2001-11-15
PL201683B1 (pl) 2009-04-30
EE04497B1 (et) 2005-06-15
BG105828A (bg) 2002-03-29
PL352330A1 (en) 2003-08-11
ATE231869T1 (de) 2003-02-15
DE60001307T2 (de) 2003-12-11
EP1161434A1 (fr) 2001-12-12
HU228671B1 (en) 2013-05-28
CZ20013102A3 (cs) 2002-01-16
US6908927B2 (en) 2005-06-21
ID30116A (id) 2001-11-08
HUP0201753A2 (en) 2002-09-28
NO327119B1 (no) 2009-04-27
EP1161434B1 (fr) 2003-01-29
AR022820A1 (es) 2002-09-04
ZA200106811B (en) 2002-08-19
KR20070086359A (ko) 2007-08-27
FR2790474B1 (fr) 2001-04-06
CN1343208A (zh) 2002-04-03
US20030187012A1 (en) 2003-10-02
EE200100470A (et) 2002-12-16
HRP20010655B1 (en) 2003-06-30
PE20001543A1 (es) 2001-03-18
TWI222975B (en) 2004-11-01
JP4806123B2 (ja) 2011-11-02
CZ302259B6 (cs) 2011-01-19
AU2922600A (en) 2000-09-28
BG65211B1 (bg) 2007-07-31
UA61164C2 (uk) 2003-11-17
BR0008763A (pt) 2002-01-02

Similar Documents

Publication Publication Date Title
TR200102403T2 (tr) Piridopiranoazepin türevleri, bunların hazırlanmaları ve terapötik uygulamaları.
HUP0001993A2 (hu) Fungicid hatású (trifluor-metil-alkil)-amino-triazol 0[1,5-a]pirimidin-származékok, előállításuk és alkalmazásuk
HUP0402180A2 (hu) Herbicid hatású szubsztituált fenilszármazékok, előállításuk és alkalmazásuk
AU2003273475A8 (en) N-(phenyl(piperidin-2-yl)methyl)benzamide derivatives, preparation thereof, and use thereof in therapy
TR200002953T2 (tr) İki halkalı hidroksamik asit türevleri
HU9700030D0 (en) 2-(1',2',4'-triazol-3'-yloxymethylene)-anilides and their use as pestcontrol agents
PT1200426E (pt) Tieno-3-il-sulfonilamino (tio) carbonil-triazolino (ti) onas substituidas
AR028649A1 (es) Derivados de 4-(2-feniltiazol-5-il)-1,4-diazabiciclo [3.2.2]nonano, su preparacion y su aplicacion en terapéutica
AR028648A1 (es) Derivados de 1,4-diazabiciclo[3.2.2]nonano-fenilisoxazol, su preparacion y su aplicacion en terapéutica
GEP20043172B (en) Combination Chemotherapy
AR028647A1 (es) Derivados de 1,4-diazabiciclo[3.2.2]nonano benzoxazol, benzotiazol y bencimidazol, su preparacion y su aplicacion en terapéutica
DE59108419D1 (de) Dicarbonsäureimide, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide
DK1001937T3 (da) Fremgangsmåde til fremstilling af 2-(3-pyrazolyloxymethylen)nitrobenzener
DK0759027T3 (da) Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
HRP20040230B1 (en) Muscarinic agonists
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
TR200000057T2 (tr) 6-pirolidin-2-ilpirindinler, hazırlanmaları ve terapötik uygulamaları.
TR199902115T2 (tr) 2,3- Dihidrofuro (3,2-b) piridiun türevleri, hazirlanislari ve terapide uygulanmalari.
NO995289D0 (no) Benzimidazol-derivater
DE59209901D1 (de) Sulfonylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung
DK0847384T3 (da) Carbamoylcarboxylsyreamider
BR0114825A (pt) Pigmentos de monoazoquinolona, processo para sua preparação e seu uso
TR200000764T2 (tr) Fosfolamban inhibitörleri olarak, 1-okza, aza ve tiyanaftalin-2-on'ların biseterleri.
EP0159692A3 (en) Annulated 4h-1,4-benzothiazine derivatives
CO5200764A1 (es) Procedimiento imidazolidin-2-onas